首页> 外文期刊>International journal of infectious diseases : >Cefazolin–gentamicin versus taurolidine–citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial
【24h】

Cefazolin–gentamicin versus taurolidine–citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial

机译:头孢唑林-庆大霉素与枸au酸他罗尔定预防血液透析患者隧道中央导管感染的准实验研究

获取原文
           

摘要

Background Catheter-related bloodstream infection (CR-BSI) is one of various complications related to hemodialysis (HD). As a result of the high rate of infection, the use of lock solutions for the prevention of CR-BSI has been studied. However, adverse effects of lock solution, such as increased emergence of strains resistant to antibiotics, which is an important concern, need to be investigated further. The aim of this study was to compare the efficacy of lock solution using a combination of cefazolin and gentamicin versus taurolidine and citrate in reducing CR-BSI in patients undergoing HD and to identify any adverse effects. Methods A prospective observational study was performed at two dialysis centers. Patients using new tunneled central venous catheters (CVC) for HD were included. Patients with a tunneled CVC were assigned to receive either antibiotic lock solution (group 1: gentamicin 7?mg/ml?+?cefazolin 12?mg/ml?+?heparin 3500?IU/ml) or lock solution with TauroLock-Hep500 (group 2: taurolidine citrate 4%?+?heparin 500 IU/ml) during the inter-dialysis period. The patients were allocated to these groups according to the hemodialysis center they were attending. Results A total of 145 CVCs were implanted in 127 patients and were followed for 15 months: 77 CVCs (65 patients) were placed in group 1 and 68 CVCs (62 patients) in group 2. There was no difference between the two groups with regard to CR-BSI (events per 1000 catheter-days: group 1?=?0.79, group 2?=?1.10; p ?=?0.18) or exit site infection rates (events per 1000 catheter-days: group 1?=?2.45, group 2?=?1.83; p ?=?0.37). The groups differed in ESI pathogens, with gram-positive oxacillin-resistant pathogens more frequent in group 1 (31.8% vs. 5.0%; p ?=?0.003). The two groups were similar in mechanical complications. In the Cox regression analysis, the internal jugular vein site was a protective factor for all catheter removal complications (hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.19–0.91) and mechanical complications (HR 0.16, 95% CI 0.065–0.41); only ESI was a risk factor for all catheter removal complications (HR 1.79, 95% CI 1.04–3.07) and mechanical complications (HR 5.64, 95% CI 1.65–19.3). Conclusions The efficacy of both lock solutions was similar in preventing infections related to tunneled CVCs for HD. However, there were more oxacillin-resistant strains in patients who received antibiotic lock solution. Further studies are required to determine the optimal drug regimen and concentrations for lock solution and the associated adverse effects.
机译:背景技术与导管相关的血液感染(CR-BSI)是与血液透析(HD)相关的各种并发症之一。由于高感染率,已经研究了使用锁定溶液预防CR-BSI。但是,锁定溶液的不利影响,例如增加对抗生素耐药性的菌株的出现,这是一个重要问题,需要进一步研究。这项研究的目的是比较使用头孢唑林和庆大霉素与牛磺酸联苯磺酸联用的锁溶液对降低HD患者的CR-BSI的疗效,并确定任何不良反应。方法在两个透析中心进行了一项前瞻性观察研究。包括使用HD的新隧道中央静脉导管(CVC)的患者。隧道性CVC患者被指定接受抗生素锁定溶液(第1组:庆大霉素7?mg / ml?+头孢唑林12?mg / ml?+肝素3500?IU / ml)或TauroLock-Hep500锁定溶液(第2组:在透析间期的柠檬酸他罗洛定4%(+)肝素(500IU / ml)。根据他们所参加的血液透析中心将患者分为这些组。结果127例患者中共植入了145个CVC,并进行了15个月的随访:第1组中放置了77例CVC(65例),第2组中放置了68例CVC(62例),两组之间无差异到CR-BSI(每1000个导管日的事件:组1 = 0.79,第2组= 1.10; p = = 0.18)或出口部位感染率(每1000个导管日的事件:1组= = 0.18)。 2.45,组2≤α= 1.83;p≤0.37)。各组的ESI病原体有所不同,第1组的革兰氏阳性抗奥沙西林病原体更为常见(31.8%vs. 5.0%; p == 0.003)。两组的机械并发症相似。在Cox回归分析中,颈内静脉部位是所有导管拔除并发症(危险比(HR)0.41,95%置信区间(CI)0.19-0.91)和机械并发症(HR 0.16,95%CI 0.065)的保护因素–0.41);仅ESI是所有导管移除并发症(HR 1.79,95%CI 1.04–3.07)和机械并发症(HR 5.64,95%CI 1.65–19.3)的危险因素。结论两种锁定解决方案在预防HD隧道CVC相关感染方面的功效相似。但是,接受抗生素锁定溶液治疗的患者对奥沙西林耐药的菌株更多。需要进一步的研究以确定最佳的药物方案和锁溶液的浓度以及相关的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号